[1] Alsheikh H. A. M., Metge B. J., Ha C. M., Hinshaw D. C., Mota M. S. V., Kammerud S. C., Lama-Sherpa T., Sharafeldin N., Wende A. R., Samant R. S., & Shevde L. A. (2021). Normalizing glucose levels reconfigures the mammary tumor immune and metabolic microenvironment and decreases metastatic seeding. Cancer letters, 517, 24-34.
[2] Shah, K. S., & Fang, J. C. (2022). Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Annual review of pharmacology and toxicology, 62, 109-120.
[3] Lazarte J., Kanagalingam T., & Hegele R. A. (2021). Lipid effects of sodium-glucose cotransporter 2 inhibitors. Current opinion in lipidology, 32(3), 183-190.
[4] Gao Z., Bao J., Hu Y., Tu J., Ye L., & Wang L. (2023). Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy. Current drug targets, 24(13), 1009-1022.
[5] DeFronzo, R. A., & Abdul-Ghani, M. (2021). Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. Diabetes spectrum : a publication of the American Diabetes Association, 34(3), 225-234.
[6] Tang J., Ye L., Yan Q., Zhang X., & Wang L. (2022). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Frontiers in pharmacology, 13, 800490.
[7] Salah H. M., Verma S., Santos-Gallego C. G., Bhatt A. S., Vaduganathan M., Khan M. S., Lopes R. D., Al'Aref S. J., McGuire D. K., & Fudim M. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. Journal of cardiovascular translational research, 15(5)
[8] 谭要鹏,李平,刘超颖. 化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性分析[J]. 临床医学工程, 2024, 31(07): 821-822.
[9] 彭显更,焦庆丽. 改良TAC方案在HER-2阴性乳腺癌新辅助化疗中的应用效果分析[J]. 中国实用医药, 2024, 19(13): 16-20.
[10] 杨蕙嘉,任章霞,顾洪,等. PD-1/PD-L1抑制剂联合含铂方案化疗治疗晚期三阴性乳腺癌的疗效[J]. 西部医学, 2024, 36(05): 719-722,727.
[11] 齐孝友,李亚彤,鲁良. 研究紫杉醇为主的联合化疗在晚期乳腺癌中的临床价值[J]. 系统医学, 2024, 9(10): 30-33. |
